S2-E64.3 – The Growing Energy and Impact of NASH Patient Advocacy
Andrew Scott joins the Surfers to discuss the growing energy and impact of patient advocacy.
January 3, 2022
Andrew Scott joins the Surfers to discuss the growing energy and impact of patient advocacy.
Jeff Lazarus joins the Surfers to discuss the emerging NAFLD Public Health Agenda.
This conversation is part of SurfingNASH’s 2021 NAFLD Year-In-Review. Co-host Dr. Stephen Harrison joins Louise Campbell and Roger Green to review five key NASH themes that emerged in 2021, while simultaneously discussing the year for Surfing the NASH Tsunami.
The last half of December marks our annual NAFLD Year-in-Review. Episodes 62-64 each include ~20 minute segments of longer interviews with Stakeholders who have made a dent in Fatty Liver disease in 2021.
Jörn Schattenberg joins the Surfers to discuss the NASH cost-effectiveness research and related findings on quality of life.
This conversation is part of SurfingNASH’s 2021 NAFLD Year-In-Review. Professor Kenneth Cusi of the University of Florida joins Louise Campbell and Roger Green to discuss
Manal Abdelmalek joins the Surfers to discuss strategies for treating cirrhotic patients today and how NASH drug development and disease knowledge will improve treatment over time.
Surfing NASH’s 2021 NAFLD year-in-review looks at the roles of older and newer drugs, multi-specialty integration against the coming NASH pandemic, and cost-effective, patient-focused healthcare.
Wayne Eskridge joins the Surfers to discuss the patient-initiated SUNN study and the significance not only of the results but also of the idea that a patient advocacy group could foster this kind of trial.
Alina Allen joins the Surfers to discuss major advances in knowledge about MRE as the foundational test for patients.
Mazen Noureddin joins the Surfers to discuss several ways that AI in histopathology can strengthen analysis in drug trials, approval processes and patient management.
SurfingNASH’s 2021 NAFLD year-in-review looks at artificial intelligence, non-invasive testing and patient activism.
Panelist and audience members debate the line of therapy for bariatric surgery.
We discuss how weight loss and GLP-1s or Double/Triple Agonists in relation to SPLENDOR.
SPLENDOR lead author Ali Amirian Shares Novel Insights About the Impact of Bariatric Surgery on MACE and MALO
Lead Author Ali Aminian shares key findings from the SPLENDOR study.
How much impact can bariatric surgery have on MACE and MALO? SPLENDOR shows and lead author Ali Aminian tells!
Learn about the non-invasive sessions, including fireside chats, and discussion of novel targets at NASH-TAG 2022
Learn about the consortium updates and artificial intelligence content at NASH-TAG 2022
Learn about the drug development content at NASH-TAG 2022
The Surfers and guest Jörn Schattenberg review NASH-TAG 2022, a unique event and the first meeting on the 2022 NAFLD and NASH calendar.
Lead author Jeffrey Lazarus and co-author Jörn Schattenberg join Stephen Harrison, Louise Campbell and Roger Green to discuss the groundbreaking paper “Advancing the Global Health Agenda for NAFLD.”
Lead author Jeffrey Lazarus and co-author Jörn Schattenberg join Stephen Harrison, Louise Campbell and Roger Green to discuss the groundbreaking paper “Advancing the Global Health Agenda for NAFLD.” This conversation focuses on the question “What’s Next,” which makes the scale of the challenge clear and compelling.
Lead author Jeffrey Lazarus and co-author Jörn Schattenberg join Stephen Harrison, Louise Campbell and Roger Green to discuss the groundbreaking paper “Advancing the Global Health Agenda for NAFLD.”
Lead author Jeffrey Lazarus and co-author Jörn Schattenberg join Stephen Harrison, Louise Campbell and Roger Green to discuss the groundbreaking paper “Advancing the Global Health Agenda for NAFLD.” In this conversation, Jeff discusses how the study was executed, Jörn describes his role and Stephen Harrison comments from a physician’s perspective.
